| Literature DB >> 17899313 |
Matthew R G Taylor1,2, Lisa Ku3, Dobromir Slavov3, Jean Cavanaugh4, Mark Boucek4, Xiao Zhu3, Sharon Graw3, Elisa Carniel3, Carl Barnes3, Dianna Quan3, Ryan Prall3, Mark A Lovell4, Gary Mierau4, Patsy Ruegg3, Naresh Mandava3, Michael R Bristow3, Jeffrey A Towbin5, Luisa Mestroni3.
Abstract
X-linked dilated cardiomyopathy (XLCM) was first described in 1987 and associated with dystrophin gene (DMD) mutations a decade later in one of the original two families. Here we report long-term follow-up of the second family (XLCM-2), for which a DMD mutation was never found. Analysis of the lysosome-associated membrane protein-2 (LAMP-2) gene detected a novel mutation, confirming a diagnosis of Danon disease. The broad phenotype in this family included dilated and hypertrophic cardiomyopathy, cardiac pre-excitation, skeletal myopathy with high serum creatinine kinase, cognitive impairement (in males), and and a pigmentary retinopathy in affected females. Cardiac biopsy in a 13-month-old mutation-carrying male showed no vacuolization by standard histology. We conclude that XLCM may be the presenting sign of Danon disease and, in the presence of familial history of HCM, pre-excitation, skeletal muscle involvement and retinal pigmentary dystrophy should prompt LAMP-2 clinical testing. Furthermore, the absence of vacuolar myopathy in biopsies from young patients may not exclude Danon disease.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17899313 DOI: 10.1007/s10038-007-0184-8
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172